{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:13:36Z","timestamp":1793805216980,"version":"4.6.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02971-7","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T10:21:54Z","timestamp":1766571714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Glucagon-like peptide-1 receptor agonists and risk for cardiovascular events in older adults treated with levothyroxine: a target trial emulation"],"prefix":"10.1186","volume":"24","author":[{"given":"Fanxing","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naykky M. Singh","family":"Ospina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan P.","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozalina G.","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Cicali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianze","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"issue":"4","key":"2971_CR1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s44161-024-00453-9","volume":"3","author":"RG McCoy","year":"2024","unstructured":"McCoy RG, Herrin J, Swarna KS, Deng Y, Kent DM, Ross JS, et al. Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk. Nat Cardiovasc Res. 2024;3(4):431\u201340.","journal-title":"Nat Cardiovasc Res"},{"key":"2971_CR2","unstructured":"FDA Approves New Drug Treatment for Chronic Weight Management [https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treatment-chronic-weight-management-first-2014]"},{"issue":"1","key":"2971_CR3","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.2337\/dc23-S009","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes. Diabetes Care. 2023;46(1):S140\u201357.","journal-title":"Diabetes Care"},{"issue":"2","key":"2971_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","volume":"6","author":"MA Bethel","year":"2018","unstructured":"Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105\u201313.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"2971_CR5","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2971_CR6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"12","key":"2971_CR7","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113\u201324.","journal-title":"N Engl J Med"},{"issue":"12","key":"2971_CR8","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384.","journal-title":"N Engl J Med"},{"issue":"15","key":"2971_CR9","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394\u2013407.","journal-title":"N Engl J Med"},{"issue":"14","key":"2971_CR10","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/ajhp\/zxac102","volume":"79","author":"EM Tichy","year":"2022","unstructured":"Tichy EM, Hoffman JM, Suda KJ, Rim MH, Tadrous M, Cuellar S, et al. National trends in prescription drug expenditures and projections for 2022. Am J Health Syst Pharm. 2022;79(14):1158\u201372.","journal-title":"Am J Health Syst Pharm"},{"key":"2971_CR11","unstructured":"Estimates of Diabetes and Its Burden in the United States. National Diabetes Statistics Report website [https:\/\/www.cdc.gov\/diabetes\/data\/statistics-report\/index.html]"},{"key":"2971_CR12","unstructured":"Stierman B, Afful J, Carroll MD, Chen TC, Davy O, Fink S, Fryar CD, Gu Q, Hales CM, Hughes JP et al: National Health and Nutrition Examination Survey 2017-March 2020 Prepandemic Data Files-Development of Files and Prevalence Estimates for Selected Health Outcomes. Natl Health Stat Report 2021(158)."},{"issue":"9","key":"2971_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023811","volume":"11","author":"R Adhikari","year":"2022","unstructured":"Adhikari R, Jha K, Dardari Z, Heyward J, Blumenthal RS, Eckel RH, et al. National trends in use of Sodium-glucose Cotransporter-2 inhibitors and Glucagon-like Peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020. J Am Heart Assoc. 2022;11(9):e023811.","journal-title":"J Am Heart Assoc"},{"issue":"Suppl 1","key":"2971_CR14","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/j.dsx.2016.12.017","volume":"11","author":"MV Jali","year":"2017","unstructured":"Jali MV, Kambar S, Jali SM, Pawar N, Nalawade P. Prevalence of thyroid dysfunction among type 2 diabetes mellitus patients. Diabetes Metab Syndr. 2017;11(Suppl 1):S105-s108.","journal-title":"Diabetes Metab Syndr"},{"issue":"8","key":"2971_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.medcli.2022.09.022","volume":"160","author":"JJ D\u00edez","year":"2023","unstructured":"D\u00edez JJ, Iglesias P. Prevalence of diabetes in people with thyroid dysfunction. Med Clin (Barc). 2023;160(8):333\u201340.","journal-title":"Med Clin (Barc)"},{"issue":"1","key":"2971_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13643-024-02527-y","volume":"13","author":"R Hadgu","year":"2024","unstructured":"Hadgu R, Worede A, Ambachew S. Prevalence of thyroid dysfunction and associated factors among adult type 2 diabetes mellitus patients, 2000\u20132022: a systematic review and meta-analysis. Syst Rev. 2024;13(1):119.","journal-title":"Syst Rev"},{"issue":"1","key":"2971_CR17","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac172","volume":"7","author":"KL Wyne","year":"2022","unstructured":"Wyne KL, Nair L, Schneiderman CP, Pinsky B, Antunez Flores O, Guo D, et al. Hypothyroidism prevalence in the United States: a retrospective study combining national health and nutrition examination survey and claims data, 2009\u20132019. J Endocr Soc. 2022;7(1):bvac172.","journal-title":"J Endocr Soc"},{"issue":"4","key":"2971_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000356507","volume":"2","author":"SH Pearce","year":"2013","unstructured":"Pearce SH, Brabant G, Duntas LH, Monzani F, Peeters RP, Razvi S, et al. 2013 ETA guideline: management of subclinical hypothyroidism. Eur Thyroid J. 2013;2(4):215\u201328.","journal-title":"Eur Thyroid J"},{"issue":"12","key":"2971_CR19","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1089\/thy.2014.0028","volume":"24","author":"J Jonklaas","year":"2014","unstructured":"Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670\u2013751.","journal-title":"Thyroid"},{"key":"2971_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1026262","volume":"13","author":"MD Ettleson","year":"2022","unstructured":"Ettleson MD, Papaleontiou M. Evaluating health outcomes in the treatment of hypothyroidism. Front Endocrinol (Lausanne). 2022;13:1026262.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2971_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-022-00357-7","volume":"8","author":"L Chaker","year":"2022","unstructured":"Chaker L, Razvi S, Bensenor IM, Azizi F, Pearce EN, Peeters RP. Hypothyroidism. Nat Rev Dis Primers. 2022;8(1):30.","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 2","key":"2971_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s12325-019-01078-2","volume":"36","author":"LH Duntas","year":"2019","unstructured":"Duntas LH, Jonklaas J. Levothyroxine dose adjustment to optimise therapy throughout a patient\u2019s lifetime. Adv Ther. 2019;36(Suppl 2):30\u201346.","journal-title":"Adv Ther"},{"issue":"4","key":"2971_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/cen.14901","volume":"99","author":"SA Tee","year":"2023","unstructured":"Tee SA, Tsatlidis V, Razvi S. The GLP-1 receptor agonist exenatide reduces serum TSH by its effect on body weight in people with type 2 diabetes. Clin Endocrinol (Oxf). 2023;99(4):401\u20138.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2971_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1159\/000501895","volume":"8","author":"ME Sencar","year":"2019","unstructured":"Sencar ME, Sakiz D, Calapkulu M, Hepsen S, Kizilgul M, Ozturk IU, et al. The effect of Exenatide on thyroid-stimulating hormone and thyroid volume. Eur Thyroid J. 2019;8(6):307\u201311.","journal-title":"Eur Thyroid J"},{"issue":"6","key":"2971_CR25","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.soard.2021.02.028","volume":"17","author":"C Azran","year":"2021","unstructured":"Azran C, Hanhan-Shamshoum N, Irshied T, Ben-Shushan T, Dicker D, Dahan A, et al. Hypothyroidism and levothyroxine therapy following bariatric surgery: a systematic review, meta-analysis, network meta-analysis, and meta-regression. Surg Obes Relat Dis. 2021;17(6):1206\u201317.","journal-title":"Surg Obes Relat Dis"},{"issue":"2","key":"2971_CR26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.soard.2019.01.001","volume":"15","author":"C Azran","year":"2019","unstructured":"Azran C, Porat D, Fine-Shamir N, Hanhan N, Dahan A. Oral levothyroxine therapy postbariatric surgery: biopharmaceutical aspects and clinical effects. Surg Obes Relat Dis. 2019;15(2):333\u201341.","journal-title":"Surg Obes Relat Dis"},{"key":"2971_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1333033","volume":"15","author":"Z Tian","year":"2024","unstructured":"Tian Z, Nie Y, Li Z, Wang P, Zhang N, Hei X, et al. Total weight loss induces the alteration in thyroid function after bariatric surgery. Front Endocrinol (Lausanne). 2024;15:1333033.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"2971_CR28","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1080\/17425255.2021.1955856","volume":"17","author":"C Hauge","year":"2021","unstructured":"Hauge C, Breitschaft A, Hartoft-Nielsen ML, Jensen S, B\u00e6kdal TA. Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjects: an open-label, one-sequence crossover, single-center, multiple-dose, two-part trial. Expert Opin Drug Metab Toxicol. 2021;17(9):1139\u201348.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2971_CR29","unstructured":"Little D DJ, Bartelt K, Longo J. Patients Who Lose Weight After Starting GLP-1s More Likely to See Thyroid Level Improvement. Epic Research. [https:\/\/epicresearch.org\/articles\/patients-who-lose-weight-after-starting-glp-1s-more-likely-to-see-thyroid-level-improvement]"},{"issue":"1","key":"2971_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01423-2","volume":"20","author":"F Alijla","year":"2021","unstructured":"Alijla F, Buttia C, Reichlin T, Razvi S, Minder B, Wilhelm M, et al. Association of diabetes with atrial fibrillation types: a systematic review and meta-analysis. Cardiovasc Diabetol. 2021;20(1):230.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2971_CR31","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032277","volume":"13","author":"R Sha","year":"2024","unstructured":"Sha R, Baines O, Hayes A, Tompkins K, Kalla M, Holmes AP, et al. Impact of obesity on atrial fibrillation pathogenesis and treatment options. J Am Heart Assoc. 2024;13(1):e032277.","journal-title":"J Am Heart Assoc"},{"key":"2971_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.01847","volume":"9","author":"EA Homan","year":"2018","unstructured":"Homan EA, Reyes MV, Hickey KT, Morrow JP. Clinical overview of obesity and diabetes mellitus as risk factors for atrial fibrillation and sudden cardiac death. Front Physiol. 2018;9:1847.","journal-title":"Front Physiol"},{"issue":"7","key":"2971_CR33","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1007\/s11606-023-08589-3","volume":"39","author":"Y Xu","year":"2024","unstructured":"Xu Y, Boyle TA, Lyu B, Ballew SH, Selvin E, Chang AR, et al. Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study. J Gen Intern Med. 2024;39(7):1112\u201321.","journal-title":"J Gen Intern Med"},{"issue":"8","key":"2971_CR34","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1177\/17474930241253988","volume":"19","author":"A Adamou","year":"2024","unstructured":"Adamou A, Barkas F, Milionis H, Ntaios G. Glucagon-like peptide-1 receptor agonists and stroke: a systematic review and meta-analysis of cardiovascular outcome trials. Int J Stroke. 2024;19(8):876\u201387.","journal-title":"Int J Stroke"},{"issue":"3\u20134","key":"2971_CR35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.vph.2009.10.001","volume":"52","author":"N Tribulova","year":"2010","unstructured":"Tribulova N, Knezl V, Shainberg A, Seki S, Soukup T. Thyroid hormones and cardiac arrhythmias. Vascul Pharmacol. 2010;52(3\u20134):102\u201312.","journal-title":"Vascul Pharmacol"},{"key":"2971_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ahj.2020.09.016","volume":"232","author":"IY Gong","year":"2021","unstructured":"Gong IY, Atzema CL, Lega IC, Austin PC, Na Y, Rochon PA, et al. Levothyroxine dose and risk of atrial fibrillation: a nested case-control study. Am Heart J. 2021;232:47\u201356.","journal-title":"Am Heart J"},{"issue":"6","key":"2971_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2024.102185","volume":"64","author":"L Wilcox","year":"2024","unstructured":"Wilcox L, Van Dril E. Suppressed thyroid stimulating hormone levels after initiation of a subcutaneous glucagon-like peptide-1 receptor agonist in a post-thyroidectomy patient managed with levothyroxine case report. J Am Pharm Assoc (2003). 2024;64(6):102185.","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"8","key":"2971_CR38","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758\u201364.","journal-title":"Am J Epidemiol"},{"issue":"6","key":"2971_CR39","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/EDE.0b013e3181875e61","volume":"19","author":"MA Hern\u00e1n","year":"2008","unstructured":"Hern\u00e1n MA, Alonso A, Logan R, Grodstein F, Michels KB, Willett WC, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19(6):766\u201379.","journal-title":"Epidemiology"},{"issue":"24","key":"2971_CR40","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","volume":"328","author":"MA Hern\u00e1n","year":"2022","unstructured":"Hern\u00e1n MA, Wang W, Leaf DE. Target trial emulation: a framework for causal inference from observational data. JAMA. 2022;328(24):2446\u20137.","journal-title":"JAMA"},{"key":"2971_CR41","doi-asserted-by":"crossref","unstructured":"Zhao JZ, Ruzieh M, Du F, Lian Y, Foy AJ, Platt RW, et al. Association between use of WATCHMAN device and 1-year mortality using high-dimensional propensity scores to reduce confounding. Circ Cardiovasc Qual Outcomes. 2025; Apr;18(4):e011188.","DOI":"10.1161\/CIRCOUTCOMES.124.011188"},{"issue":"10296","key":"2971_CR42","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","volume":"398","author":"E Brown","year":"2021","unstructured":"Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021;398(10296):262\u201376.","journal-title":"Lancet"},{"issue":"7","key":"2971_CR43","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/eurjpc\/zwad356","volume":"31","author":"HD Zhang","year":"2024","unstructured":"Zhang HD, Ding L, Mi LJ, Zhang AK, Zhang K, Jiang ZH, et al. Sodium-glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis. Eur J Prev Cardiol. 2024;31(7):770\u20139.","journal-title":"Eur J Prev Cardiol"},{"issue":"15","key":"2971_CR44","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1001\/archinte.164.15.1675","volume":"164","author":"L Frost","year":"2004","unstructured":"Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med. 2004;164(15):1675\u20138.","journal-title":"Arch Intern Med"},{"issue":"Suppl 1","key":"2971_CR45","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab048.1923","volume":"5","author":"TN Lanham","year":"2021","unstructured":"Lanham TN, Morgan FH. Management of atrial flutter in thyroid storm. J Endocr Soc. 2021;5(Suppl 1):A941.","journal-title":"J Endocr Soc"},{"issue":"4","key":"2971_CR46","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/acem.13140","volume":"24","author":"AK Venkatesh","year":"2017","unstructured":"Venkatesh AK, Mei H, Kocher KE, Granovsky M, Obermeyer Z, Spatz ES, et al. Identification of emergency department visits in Medicare administrative claims: approaches and implications. Acad Emerg Med. 2017;24(4):422\u201331.","journal-title":"Acad Emerg Med"},{"issue":"12","key":"2971_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-021-01611-2","volume":"23","author":"W Bode","year":"2021","unstructured":"Bode W, Ptaszek LM. Management of atrial fibrillation in the emergency department. Curr Cardiol Rep. 2021;23(12):179.","journal-title":"Curr Cardiol Rep"},{"issue":"S","key":"2971_CR48","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.15441\/ceem.23.153","volume":"10","author":"SE Lee","year":"2023","unstructured":"Lee SE, Kim HJ, Ro YS. Epidemiology of stroke in emergency departments: a report from the National Emergency Department Information System (NEDIS) of Korea, 2018\u20132022. Clin Exp Emerg Med. 2023;10(S):S48-s54.","journal-title":"Clin Exp Emerg Med"},{"issue":"9","key":"2971_CR49","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1093\/aje\/kwad091","volume":"192","author":"T Jiao","year":"2023","unstructured":"Jiao T, Platt RW, Douros A, Filion KB. Use of a statistical adaptive treatment strategy approach for emulating randomized controlled trials using observational data: the example of blood-pressure control strategies for the prevention of cardiovascular events among individuals with hypertension at high cardiovascular risk. Am J Epidemiol. 2023;192(9):1576\u201391.","journal-title":"Am J Epidemiol"},{"key":"2971_CR50","first-page":"335","volume":"44","author":"PC Dischinger","year":"2000","unstructured":"Dischinger PC, Ho SM, Kufera JA. Medical conditions and car crashes. Annu Proc Assoc Adv Automot Med. 2000;44:335\u201346.","journal-title":"Annu Proc Assoc Adv Automot Med"},{"issue":"4","key":"2971_CR51","doi-asserted-by":"publisher","first-page":"734","DOI":"10.2105\/AJPH.2004.058156","volume":"96","author":"S Zhu","year":"2006","unstructured":"Zhu S, Layde PM, Guse CE, Laud PW, Pintar F, Nirula R, et al. Obesity and risk for death due to motor vehicle crashes. Am J Public Health. 2006;96(4):734\u20139.","journal-title":"Am J Public Health"},{"issue":"14","key":"2971_CR52","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317\u201326.","journal-title":"N Engl J Med"},{"issue":"14","key":"2971_CR53","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327\u201335.","journal-title":"N Engl J Med"},{"issue":"3","key":"2971_CR54","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232\u201342.","journal-title":"N Engl J Med"},{"issue":"10","key":"2971_CR55","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1001\/jamainternmed.2024.2919","volume":"184","author":"KE Karakus","year":"2024","unstructured":"Karakus KE, Shah VN, Akturk HK. Tirzepatide-induced rapid weight loss-related thyrotoxicosis. JAMA Intern Med. 2024;184(10):1246\u20137.","journal-title":"JAMA Intern Med"},{"issue":"1 Suppl 1","key":"2971_CR56","first-page":"S181","volume":"48","author":"Pharmacologic Approaches to Glycemic Treatment","year":"2025","unstructured":"Pharmacologic Approaches to Glycemic Treatment. Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S181-s206.","journal-title":"Diabetes Care"},{"issue":"4","key":"2971_CR57","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"10193","key":"2971_CR58","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"key":"2971_CR59","doi-asserted-by":"crossref","unstructured":"Cesaro A, Pastori D, Acerbo V, Biccir\u00e8 FG, Golino M, Panico D, Prati F, Abbate A, Lip GYH, Calabr\u00f2 P: Reduction of New Onset of Atrial Fibrillation in Patients Treated with Semaglutide: An updated systematic review and meta regression analysis of randomized controlled trials. Eur J Prev Cardiol 2025; Apr 28:zwaf257.","DOI":"10.1093\/eurjpc\/zwaf257"},{"key":"2971_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100679","volume":"18","author":"FB Rivera","year":"2024","unstructured":"Rivera FB, Cruz LLA, Magalong JV, Ruyeras J, Aparece JP, Bantayan NRB, et al. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Am J Prev Cardiol. 2024;18:100679.","journal-title":"Am J Prev Cardiol"},{"issue":"1","key":"2971_CR61","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","volume":"13","author":"SV Badve","year":"2025","unstructured":"Badve SV, Bilal A, Lee MMY, Sattar N, Gerstein HC, Ruff CT, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025;13(1):15\u201328.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"22","key":"2971_CR62","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"2971_CR63","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"15","key":"2971_CR64","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","volume":"141","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial. Circulation. 2020;141(15):1227\u201334.","journal-title":"Circulation"},{"issue":"3","key":"2971_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101615","volume":"4","author":"V Jaiswal","year":"2025","unstructured":"Jaiswal V, Ang SP, Kumar D, Deb N, Jaiswal A, Joshi A, et al. Sodium-glucose cotransporter-2 inhibitors and arrhythmias: a meta-analysis of 38 randomized controlled trials. JACC Adv. 2025;4(3):101615.","journal-title":"JACC Adv"},{"issue":"1","key":"2971_CR66","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13098-025-01635-6","volume":"17","author":"A Mousavi","year":"2025","unstructured":"Mousavi A, Shojaei S, Soleimani H, Semirani-Nezhad D, Ebrahimi P, Zafari A, et al. Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2025;17(1):68.","journal-title":"Diabetol Metab Syndr"},{"issue":"12","key":"2971_CR67","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1007\/s11695-017-2965-2","volume":"27","author":"B Guan","year":"2017","unstructured":"Guan B, Chen Y, Yang J, Yang W, Wang C. Effect of bariatric surgery on thyroid function in obese patients: a systematic review and meta-analysis. Obes Surg. 2017;27(12):3292\u2013305.","journal-title":"Obes Surg"},{"issue":"15","key":"2971_CR68","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1161\/CIRCULATIONAHA.106.678326","volume":"116","author":"I Klein","year":"2007","unstructured":"Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007;116(15):1725\u201335.","journal-title":"Circulation"},{"issue":"5","key":"2971_CR69","doi-asserted-by":"publisher","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","volume":"326","author":"B Park","year":"2024","unstructured":"Park B, Bakbak E, Teoh H, Krishnaraj A, Dennis F, Quan A, et al. GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage. Am J Physiol Heart Circ Physiol. 2024;326(5):H1159-h1176.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"2971_CR70","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s13300-015-0127-x","volume":"6","author":"A Uccellatore","year":"2015","unstructured":"Uccellatore A, Genovese S, Dicembrini I, Mannucci E, Ceriello A. Comparison review of short-acting and long-acting Glucagon-like Peptide-1 receptor agonists. Diabetes Ther. 2015;6(3):239\u201356.","journal-title":"Diabetes Ther"},{"issue":"43","key":"2971_CR71","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035739","volume":"102","author":"X Yuan","year":"2023","unstructured":"Yuan X, Gao Z, Hao Z, Ma H, Duan K, Yang C. Effect of long-acting versus short-acting glucagon-like peptide-1 receptor agonists on improving body weight and related metabolic parameters in type 2 diabetes: a head-to-head meta-analysis. Medicine (Baltimore). 2023;102(43):e35739.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2971_CR72","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/dom.12596","volume":"18","author":"S Madsbad","year":"2016","unstructured":"Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18(4):317\u201332.","journal-title":"Diabetes Obes Metab"},{"key":"2971_CR73","doi-asserted-by":"crossref","unstructured":"Pinto M, Brennan L, Diehl K, Lin S, Heacock S: Real-World Comparison of Oral Versus Injectable Semaglutide for the Reduction of Hemoglobin A(1C) and Weight in Patients with Type 2 Diabetes. J Pharm Technol 2024:87551225241289959.","DOI":"10.1177\/87551225241289959"},{"issue":"8","key":"2971_CR74","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.2337\/dc20-0190","volume":"43","author":"CK Rayner","year":"2020","unstructured":"Rayner CK, Watson LE, Phillips LK, Lange K, Bound MJ, Grivell J, et al. Effects of sustained treatment with lixisenatide on gastric emptying and postprandial glucose metabolism in type 2 diabetes: a randomized controlled trial. Diabetes Care. 2020;43(8):1813\u201321.","journal-title":"Diabetes Care"},{"issue":"3","key":"2971_CR75","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark TJ Jr, et al. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid. 2021;31(3):337\u201386.","journal-title":"Thyroid"},{"issue":"2","key":"2971_CR76","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.55838","volume":"6","author":"S Khurshid","year":"2023","unstructured":"Khurshid S, Ashburner JM, Ellinor PT, McManus DD, Atlas SJ, Singer DE, et al. Prevalence and incidence of atrial fibrillation among older primary care patients. JAMA Netw Open. 2023;6(2):e2255838.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"2971_CR77","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1001\/jamaneurol.2024.2044","volume":"81","author":"JA Columbo","year":"2024","unstructured":"Columbo JA, Daya N, Colantonio LD, Wang Z, Foti K, Hyacinth HI, et al. Derivation and validation of ICD-10 codes for identifying incident stroke. JAMA Neurol. 2024;81(8):875\u201381.","journal-title":"JAMA Neurol"},{"issue":"Suppl 1(0 1)","key":"2971_CR78","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/pds.2317","volume":"21","author":"PN Jensen","year":"2012","unstructured":"Jensen PN, Johnson K, Floyd J, Heckbert SR, Carnahan R, Dublin S. A systematic review of validated methods for identifying atrial fibrillation using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1(0 1)):141\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"2971_CR79","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/europace\/eut048","volume":"15","author":"C Ohlmeier","year":"2013","unstructured":"Ohlmeier C, Mikolajczyk R, Haverkamp W, Garbe E. Incidence, prevalence, and antithrombotic management of atrial fibrillation in elderly Germans. Europace. 2013;15(10):1436\u201344.","journal-title":"Europace"},{"issue":"2","key":"2971_CR80","first-page":"S325","volume":"58","author":"M Kelly-Hayes","year":"2010","unstructured":"Kelly-Hayes M. Influence of age and health behaviors on stroke risk: lessons from longitudinal studies. J Am Geriatr Soc. 2010;58(2):S325-328.","journal-title":"J Am Geriatr Soc"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02971-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02971-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02971-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:02:52Z","timestamp":1766577772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-025-02971-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2971"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02971-7","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol received approval from the Institutional Review Board at the University of Florida, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"459"}}